Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region
Background & Objectives: Biological disease-modifying antirheumatic drugs (bDMARDs) for the treatment of rheumatoid arthritis (RA) are not always accessible to all patients in accordance with international guidelines, partly owing to their high direct costs against a background of restricted healthc...
Uloženo v:
| Hlavní autoři: | , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
MDPI AG
2017-01-01
|
| Edice: | Journal of Market Access & Health Policy |
| Témata: | |
| On-line přístup: | http://dx.doi.org/10.1080/20016689.2017.1345580 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|